RCT: Effect of intravitreous anti–vascular endothelial growth factor vs. sham treatment for prevention of vision-threatening complications of diabetic retinopathy

Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial – JAMA Ophthalmology

Commentaries: Preventive treatment reduces diabetic retinopathy complications – NIH News Releases AND Prevention of Severe Nonproliferative Diabetic Retinopathy Progression With More at Stake Than Visual Acuity – JAMA Ophthalmology AND Practicality of Prophylactic Aflibercept to Reduce Diabetic Retinopathy Progression – JAMA Ophthalmology

Author interview: Randomized Trial of Anti-VEGF to Prevent Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema (DME) – JAMA

Commentary on Twitter

In this study, aflibercept injections reduced the development of vision-threating complications; however, through 2 years, preventive treatment did not confer visual acuity benefit compared with observation plus aflibercept if complications developed https://t.co/q4ABSKOMVj

— JAMAOphthalmology (@JAMAOphth) March 30, 2021